Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Advanced Solid Tumors
Interventions: Elimusertib (BAY1895344), Pembrolizumab (Keytruda®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more

Conditions: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
Interventions: NDI-101150, Pembrolizumab; Drug
Lead sponsor: Nimbus Saturn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Advanced Solid Tumor, Advanced Solid Malignancies
Interventions: PRJ1-3024; Drug
Lead sponsor: Zhuhai Yufan Biotechnologies Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • Cincinnati, Ohio + 3 more

Conditions: HPV-Related Carcinoma
Interventions: IBRX-042; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 2
States / cities: El Segundo, California • Houston, Texas

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: L-778,123, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions: yttrium Y 90-edotreotide; Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
Interventions: TURALIO(R); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 35 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Keratosis
Interventions: PEP005; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Colorectal Cancer (CRC), Gastric Cancer
Interventions: SC-007; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Rochester, Minnesota • St Louis, Missouri + 4 more

Conditions: Hematologic Malignancies
Interventions: MultiStem®; Biological
Lead sponsor: Healios K.K.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Phoenix, Arizona • Cleveland, Ohio • Portland, Oregon + 2 more

Conditions: Prostate Cancer
Interventions: Elesclomol Sodium, Docetaxel; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Fountain Valley, California • Rochester, Maryland • Bismarck, North Dakota + 2 more

Conditions: T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions: Fenretinide; Drug
Lead sponsor: SciTech Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more

Conditions: Chronic Lymphoproliferative Diseases
Interventions: GRN163L; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 8
States / cities: Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more

Conditions: Cancer, Neoplasm, Neoplasm Metastasis
Interventions: VNP20009; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions: L-377202; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Medical Oncology
Interventions: BAY1143269 tablet; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • San Antonio, Texas

Conditions: Osteosarcoma, Bone Metastases
Interventions: 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product; Drug · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 15 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Belinostat, Carboplatin, Paclitaxel; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more

Conditions: Multiple Myeloma
Interventions: MLN9708; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: Refractory Solid Tumors, Lymphoma
Interventions: Terameprocol (EM-1421); Drug
Lead sponsor: Erimos Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Superficial Basal Cell Carcinoma
Interventions: PEP005; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 9
States / cities: Mesa, Arizona • Oceanside, California • San Diego, California + 6 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study, positron emission tomography; Drug · Other · Procedure
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Advanced Hematologic Malignancies
Interventions: CPI-613; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Refractory Solid Tumors
Interventions: MPC-6827; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Houston, Texas • Salt Lake City, Utah

Search by objective public record fields.

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

A Study of NDI 1150-101 in Patients With Solid Tumors

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

IBRX-042 In Participants With HPV-Associated Tumors

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

A Study of SC-007 in Subjects With Advanced Cancer

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria

Study Evaluating the Safety and Tolerability of L-377202

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors